Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 6/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8048511 | 0.86 | ACP3 (0.42) | ACP3PTPRCPTK2BL3MBTL1KDM4E | |
| SCHEMBL7611154 | 0.83 | ACP3 (0.42) | ACP3PTPRCL3MBTL1KDM4ELMNA | |
| SCHEMBL7613491 | 0.80 | ACP3 (0.44) | ACP3PTPRCKDM4EPPARGPPARA | |
| SCHEMBL8046802 | 0.79 | ACP3 (0.39) | ACP3HPGDCETPPPARGPPARA | |
| SCHEMBL5053316 | 0.79 | ACP3 (0.39) | ACP3L3MBTL1KDM4ELMNAHPGD | |
| SCHEMBL7611836 | 0.79 | PTPN1 (0.46) | CETPPPARGPPARA | |
| SCHEMBL7605240 | 0.79 | ACP3 (0.41) | ACP3PTPRCKDM4ELMNAHPGD | |
| SCHEMBL7608436 | 0.77 | CETP (0.40) | ACP3CETP | |
| SCHEMBL7610662 | 0.77 | ACP3 (0.40) | ACP3PTPRCPTK2BL3MBTL1KDM4E | |
| SCHEMBL8061548 | 0.76 | ACP3 (0.41) | ACP3PTPRCKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| EP-1044206-A1 | PRODRUGS OF NAALADASE INHIBITORS | Guildford Pharmaceuticals Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |